Patents by Inventor Zhili Xin

Zhili Xin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210115020
    Abstract: Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
    Type: Application
    Filed: June 26, 2019
    Publication date: April 22, 2021
    Inventors: Felix Gonzalez Lopez de Turiso, Michael Dechantsreiter, Zhili Xin, John H. Jones, Martin Himmelbauer
  • Patent number: 10968181
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: April 6, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian Stuart Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • Publication number: 20210040080
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 11, 2021
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Publication number: 20190345112
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 14, 2019
    Inventors: Brian Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • Patent number: 10273234
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: April 30, 2019
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • Patent number: 10144732
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: December 4, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Gnanasambandam Kumaravel, Hairuo Peng, Zhili Xin
  • Patent number: 10017506
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 10, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Patent number: 9944666
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 17, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Zhili Xin, Lei Zhang
  • Patent number: 9920048
    Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 20, 2018
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Patent number: 9850206
    Abstract: Compounds of formula (I) wherein: X is —O—, —S(O)r—, —CH2—, or —NR—, wherein r is 0, 1, or 2; X1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provided that no more than three of X1, X2, X3, X or X5 are N; Ring A is monocyclic C5-6scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or O; wherein Ring A is further optionally substituted with from 1 to 3 R4; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, —O—, —NR—, —S(O)n—, —CH2—, or —C(O)—, wherein n is 0, 1, or 2; 1 2 L1 is an C1-8alkylene, C3-scycloalkylene, —CH2-L2-, or a 3- to 8-membered heterocyclylene comprising 1 to 5; R1 is C6-20alkyl or a monocyclic C3-8cycloalkyl; wherein said C3-8cycloalkyl is substituted with at least one R6 and may be optionally substituted with from 1 to 5 additional R6 substituents, wherein R6 for each occurrence is inde
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: December 26, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Hairuo Peng, Edward Yin-Shiang Lin, Jianhua Chao, Zhili Xin, Bin Ma, Kevin Guckian, Timothy Chan, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9771326
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 26, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Hairuo Peng, Zhili Xin, Lihong Sun, Timothy Chan, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Publication number: 20170197960
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Application
    Filed: June 5, 2015
    Publication date: July 13, 2017
    Inventors: Gnanasambandam Kumaravel, Hairuo Peng, Zhili Xin
  • Publication number: 20170174710
    Abstract: Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).
    Type: Application
    Filed: December 2, 2016
    Publication date: June 22, 2017
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Zhili Xin, Lei Zhang
  • Publication number: 20170158686
    Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 8, 2017
    Applicants: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong CHEN, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Publication number: 20170158687
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Application
    Filed: October 18, 2016
    Publication date: June 8, 2017
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Patent number: 9555050
    Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 31, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Zhaohui Shao, Lihong Sun, Arthur Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Patent number: 9550798
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 24, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur Taveras, Zhili Xin, Lei Zhang
  • Patent number: 9522889
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: December 20, 2016
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Patent number: 9499485
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: November 22, 2016
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • Publication number: 20160039825
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Hairuo Peng, Zhili Xin, Lei Zhang, Lihong Sun, Gnanasambandam Kumaravel, Art Taveras, Deping Wang